The Journal of Clinical Investigation
C L I N I C A L M E D I C I N E, Sixten Körper, Manfred Weiss, Daniel Zickler, Thomas Wiesmann, Kai Zacharowski, Victor M Corman, Beate Grüner, Lucas Ernst, Peter Spieth, Philipp M Lepper, Martin Bentz, Sebastian Zinn, Gregor Paul, Johannes Kalbhenn, Matthias M Dollinger, Peter Rosenberger, Thomas Kirschning, Thomas Thiele, Thomas Appl, Benjamin Mayer, Michael Schmidt, Christian Drosten, Hinnerk Wulf, Jan Matthias Kruse, Bettina Jungwirth, Erhard Seifried, Hubert Schrezenmeier
doi:10.1172/JCI152264DS1).
BACKGROUND. COVID-19 convalescent plasma (CCP) has been considered a treatment option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring respiratory support or intensive care treatment.
METHODS. Patients (n = 105) were randomized 1:1 to either receive standard treatment and 3 units of CCP or standard treatment alone. Control group patients with progress on day 14 could cross over to the CCP group. The primary outcome was a dichotomous composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21.
RESULTS. The primary outcome occurred in 43.4% of patients in the CCP group and 32.7% in the control group (P = 0.32). The median time to clinical improvement was 26 days in the CCP group and 66 days in the control group (P = 0.27). The median time to discharge from the hospital was 31 days in the CCP group and 51 days in the control group (P = 0.24). In the subgroup that received a higher cumulative amount of neutralizing antibodies, the primary outcome occurred in 56.0% of the patients (vs. 32.1%), with significantly shorter intervals to clinical improvement (20 vs. 66 days, P < 0.05) and to hospital discharge (21 vs. 51 days, P = 0.03) and better survival (day-60 probability of survival 91.6% vs. 68.1%, P = 0.02) in comparison with the control group. CONCLUSION. CCP added to standard treatment was not associated with a significant improvement in the primary and secondary outcomes. A predefined subgroup analysis showed a significant benefit of CCP among patients who received a larger amount of neutralizing antibodies. TRIAL REGISTRATION. ClinicalTrials.gov NCT04433910.
Author contributions HS and SK wrote study protocol, coordinated the study, analyzed and interpreted data, and wrote the manuscript. HS, SK, and ES applied for funding. HS and ES were the lead investigators. MW, DZ, TW, KZ, BG, LE, PS, PML, MB, SZ, GP, JK, MMD, PR, TK, TT, HW, JMK, and BJ performed patient care and data collection. VMC and CD performed analysis of SARS-CoV-2 antibodies. MS performed SARS-CoV-2 PCR. TA managed the project. BM performed statistical analysis. All authors approved the manuscript.
References
Agarwal, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Alqahtani, Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease, Sci Rep,
doi:10.1038/s41598-021-89444-5Anand, Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset, Cell Rep Med,
doi:10.1016/j.xcrm.2021.100290Bajpai, Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial,
doi:10.1101/2020.10.25.20219337Balcells, Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial, PLoS Med,
doi:10.1371/journal.pmed.1003415Bloch, Deployment of convalescent plasma for the prevention and treatment of COVID-19, J Clin Invest,
doi:10.1172/JCI138745Casadevall, Pirofski, The convalescent sera option for containing COVID-19, J Clin Invest,
doi:10.1172/JCI138003Estcourt, Roberts, Convalescent plasma for Covid-19, BMJ
Gharbharan, Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection, Nat Commun,
doi:10.1038/s41467-021-23469-2Jahrsdorfer, Characterization of the SARS-CoV-2 neutralization potential of COVID-19-convalescent donors, J Immunol,
doi:10.4049/jimmunol.2100036Janiaud, Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA,
doi:10.1001/jama.2021.2747Klassen, The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis, Mayo Clin Proc,
doi:10.1016/j.mayocp.2021.02.008Kreye, A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model, Cell,
doi:10.1016/j.cell.2020.09.049Körper, Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial: donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies, Transfus Med Hemother,
doi:10.1159/000515610Li, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA
Lim, Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A meta-analysis, Am J Respir Crit Care Med,
doi:10.1164/rccm.202006-2405OCMartin-Vicente, Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission are associated to higher viral loads in plasma, antigenemia and mortality in COVID-19 patients,
doi:10.1101/2021.03.08.21253121Natarajan, Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma, mBio
O'donnell, A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19, J Clin Invest,
doi:10.1172/JCI150646Piechotta, Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review, Cochrane Database Syst Rev,
doi:10.1002/14651858.CD013600.pub2Salazar, Significantly decreased mortality in a large cohort of Coronavirus Disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) spike protein IgG, Am J Pathol,
doi:10.1016/j.ajpath.2020.10.008Simonovich, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med
Winkler, Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection, Cell,
doi:10.1016/j.cell.2021.02.026Wouters, Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary, Vox Sang,
doi:10.1111/vox.13060Zhou, Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and metaanalysis, Int J Infect Dis,
doi:10.1016/j.ijid.2020.07.029
